OXGN $2.40 Drei Krebsmedikamente in der Pipeline!

Ticker: OXGN
Preis $2.40
Webseite:www.oxigene.com
Cash: $8.5M
13,329,229 shares of outstanding
Charts:
ih.advfn.com/...=N%5Eoxgn&p=0&t=23&dm=0&vol=1" style="max-width:560px" />
stockcharts.com/c-sc/...mp;dy=0&i=p30016240397&r=6673" style="max-width:560px" />
stockcharts.com/c-sc/...mp;dy=0&i=p69203472327&r=9145" style="max-width:560px" />
stockcharts.com/c-sc/...mp;dy=0&i=p33810607142&r=7799" style="max-width:560px" />
stockcharts.com/c-sc/...amp;g=0&i=p15914534331&r=9570" style="max-width:560px" />

Der MACD ist heute den ersten Tag positiv!

2011 Best of ASCO® Miami Meeting
Friday, July 29 and Saturday, July 30, 2011
Hyatt Regency Miami

2011 Best of ASCO® Seattle Meeting
Friday, August 5 and Saturday, August 6, 2011
The Westin Seattle

..unter 2 USD könnte man ne erste Posi aufbauen! Meine Meinung und keine Kaufempfehlung

Bin mal gespannt auf die Kerze im Wochenchart am Ende dieser Woche!

OXGN hat heute einen doppelten Boden bei $2.15 geformt!
Habe heute nocheinmal meine Positionen aufgestockt.... ASCO kann kommen!

img src="elite.finviz.com/....ashx?ta=1&p=d&s=l&t=OXGN">

finviz.com/chart.ashx?t=OXGN&ty=c&ta=1&p=d&s=l" style="max-width:560px" />

OXiGENE ( $OXGN ) reports cash of approximately $8.5 million

As of July 8, 2011, shares of common stock in an aggregate offering amount of $19,156,051 have been sold under the July 21, 2010, January 1, 2011, June 1, 2011, and June 29, 2011 prospectus supplements, and no further sales of shares will be made under such prospectus supplements. Sales of common stock under the July 8, 2011 prospectus supplement will be made from time to time as market conditions warrant, in the Company's discretion.

The Agreement has been previously filed as Exhibit 10.1 to our Current Report on
Form 8-K on July 21, 2010 and is incorporated herein by reference. A copy of
the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., relating to
the legality of the shares, is filed as Exhibit 5.1 to this Current Report and
is incorporated by reference into the registration statement.
As of June 30, 2011, OXiGENE expects to report cash, cash equivalents and restricted cash of approximately $8.5 million, compared with approximately $2.7 million at March 31, 2011.

Source:
www.dailyfinance.com/company/oxigene-inc/...18/pdf/sec-filings

Sales of shares of our common stock under this prospectus, if any, may be made in privately negotiated transactions and/or any other method permitted by law, including sales deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act of 1933, as amended, which includes sales made directly on The NASDAQ Capital Market, the existing trading market for our common stock, or sales made to or through a market maker other than on an exchange. The sales agent will make all sales using commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreeable terms between the sales agent and us.
Unless we and our sales agent otherwise agree, we will pay our sales agent a commission fee of up to 5% of each sale of common stock to be sold pursuant to this prospectus. Any other fee arrangement or commission amount to be received by the sales agent will be disclosed in a separate prospectus supplement for such shares. The net proceeds to us that we receive from sales of our common stock will depend on the number of shares actually sold and the offering price for such shares. Based on the trading price of our common stock, our current public float and the absence of a minimum offering amount provided for under the sales agreement, we may not be able to raise the full $3,100,000 in gross proceeds contemplated by this prospectus supplement. The actual proceeds to us will vary.
In connection with the sales of common stock on our behalf, the sales agent will be deemed an “underwriter” within the meaning of the Securities Act of 1933, as amended, and the compensation of the sales agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the sales agent against certain liabilities, including liabilities under the Securities Act of 1933, as amended.

Nächste Woche könnte es bei OXGN endgültig nach oben gehen, da das letzte Aktienpaket im Wert von $3.1M am Markt platziert worden ist.
Das Unternehmen hat bereits in der ersten Juliwoche verkündet , dass es über genügend Cash verfügt und auf keine weitere Kapitalerhöhung innerhalb der nächsten Monate angewiesen ist.

Das Unternehmen verbrennt pro Monat etwa $1M.
Also kann man sagen, dass mindestens 8-10 Monate keine Verwässerung mehr stattfinden wird.
Des Weiteren steht die ASCO.
Phantasie besteht aus eventueller Partnergewinnung zur gemeinsamen Vermarktung eines Krebsmedikaments sowie eine potentielle Übernahme durch ein größeres Pharmaunternehmen....

Heute nocheinmal bei $1.47 meine letzte Portion OXGN Aktien gekauft der Hoffnung gute Zahlen am 10. Aug. 2011 vom Unternehmen präsentiert zu bekommen!

$OXGN - 2011 Best of ASCO® Seattle Meeting
Friday, August 5 and Saturday, August 6, 2011
The Westin Seattle

möglich (meine Meinung)

aktuell über 24 Prozent Plus!!!

sk $1.55 +39,64%

Price target on $OXGN at $4.21
hotpennystocksonline.com/?p=595

OXiGENE Reports Second Quarter 2011 Financial Results

ih.advfn.com/...pid=nmona&article=48783633&symbol=OXGN

Jederzeit für ein Verdoppelung gut! Ein paar habe ich mir heute ins Depot genommen.
Mal schauen wie sich das Ganze entwickelt....

und das bei steigendem Kurs.....

Partnership oder Buyout news sollen bald veröffentlicht werden.
Aktueller Kurs $1.33

$OXGN termination of Kingsbridge $40M deal means OXGN gonna face a buyout or a partnership with a huge biotech company!
I am buying all I can below $1.30 !

www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8189481

Termination of a Material Definitive Agreement.

On October 13, 2011, OXiGENE, Inc. (the “Company”) notified Kingsbridge Capital Limited (“Kingsbridge”) of the termination of its Committed Equity Financing Facility (“CEFF”) with Kingsbridge, pursuant to which Kingsbridge had committed to purchase, subject to certain conditions, up to $40 million of the Company’s common stock.  Effective as of October 14, 2011, the CEFF was terminated by the Company pursuant to Section 8.2(c) of the common stock purchase agreement (the “Common Stock Purchase Agreement”) with Kingsbridge, dated as of February 19, 2008, as amended.

In connection with the CEFF, on February 19, 2008, OXiGENE also issued a warrant (the “Warrant”) to Kingsbridge to purchase up to 12,500 shares of OXiGENE common stock.  The Warrant remains exercisable until August 19, 2013, subject to certain conditions.

New letter from CEO
www.oxigene.com/files/Letter_from_CEO_oct132011.pdf

...On the clinical front, shortly we expect to have the final overall survival data from our completed Phase 2 study in non-small cell lung cancer (the FALCON study) which compared the standard chemotherapy treatment regimen for these patients, consisting of
carboplatin, paclitaxel and bevacizumab with and without ZYBRESTAT. We hope to be ready to talk about these results at our upcoming quarterly earnings call in November 2011....

$AZN Partnership deal or buyout with OXGN?

Jerry McMahon Board Director @ OXiGENE, Inc.
Senior Vice President, R&D Oncology iMED Head @ MedImmune.
www.linkedin.com/pub/jerry-mcmahon/20/521/182

MedImmune , the global biologics business for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, rewarding careers to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune’s website at www.medimmune.com.

aktuell $1.35x$1.64

$8.46M soweit ich weiß

$1.53

OXGN $1.41 - Hearing a tender offer in the $3's in negotiation. eom

Tender offer soll bei $3.88 liegen! Aktueller Kurs $1.64

OXGN $1.61 next targets : $1.94 (MA100) & $2.48 (MA200) after that blue sky!

Aktueller Kurs : $1.64 Tageshoch

Im Bereich von $1.53-$1.55 hat sich ein key support ausgebildet.
Heutiger Schlusskurs liegt bei $1.59. Meiner Meinung nach werden wir nächste Woche Richtung $2+ laufen.

nachbörslich kracht es gewaltig nach unten! 1 Dollar???

Commented Peter J. Langecker, M.D., Ph.D., Chief Executive Officer of OXiGENE: "This agreement represents a critical milestone in the ongoing development of ZYBRESTAT, reflecting OXiGENE's commitment to facilitate access to this potentially valuable therapy by ATC patients who have no other treatment options. We are delighted to work in partnership with Azanta, a privately held European specialty pharmaceutical company with specialized technical and regulatory expertise in implementing compassionate use programs. While Azanta focuses on our Named Patient Program, we will continue to pursue a global regulatory strategy for ZYBRESTAT in ATC, including seeking additional financing for the FACT 2 study, with the goal of initiating this pivotal trial in 2012."

Commented Claus Moeller, Chief Executive Officer of Azanta: "Partnering with OXiGENE to distribute ZYBRESTAT to European and Canadian ATC patients under appropriate regulatory auspices reflects our strategy to build industry leadership by making innovative developmental therapies available to patients in international markets. We believe that ZYBRESTAT has generated an impressive body of safety and activity data, with a suggested survival benefit in ATC, and has significant therapeutic and commercial potential. We are pleased to make our distribution and regulatory expertise available to help advance this promising therapeutic option, and we look forward to a productive collaboration."

About ZYBRESTAT

OXiGENE believes that ZYBRESTAT is poised to become an important therapeutic option in a novel class of small-molecule drug candidates called vascular disrupting agents. Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has shown potent and selective activity against tumor vasculature, as well as possible clinical activity against anaplastic thyroid cancer, ovarian cancer and various other solid tumors.

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company's major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4969

About Azanta

Azanta A/S is a specialty pharma company primarily operating within oncology, women's health and addiction medicine. The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical concepts. Azanta A/S currently markets or makes available nine specialty pharma products in the Nordic region and in the U.K., including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy. In addition, Azanta A/S has a portfolio of low risk development projects which are planned to be commercialized within the next two to three years.

The Azanta Danmark A/S logo is available at www.globenewswire.com/newsroom/prs/?pkgid=11229

Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include possible outcomes of clinical studies involving ZYBRESTAT, interest among potential partners or regulatory filings and outcomes, may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the outcome of clinical studies and the availability of additional financing to continue development of ZYBRESTAT. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

CONTACT: Investor and Media Contact:
ir@oxigene.com
650-635-7000

Einkauf heute zu $1.10 - Akite hat einen extremen Boden gebildet und könnte erst einmal das Gap bei $1.65 schließen!

finviz.com/chart.ashx?t=OXGN&ty=c&ta=1&p=d&s=l" style="max-width:560px" />

Mkt Cap (Mil) $15.62 bei $1.11
Shares Out (Mil) 14.88
Float (Mil) 13.04
www.dailyfinance.com/quote/nasdaq/...e-inc/oxgn/key-statistics
finance.yahoo.com/q/ks?s=OXGN+Key+Statistics

Ausgestoppt bei $1.06 - volumen hat nachgelassen.

Bruch der $1.37 wird die Aktie schnell Richtung $1.68 ( gap fill ) katapultieren!

kommen und der Deckel fliegen. Sag nur Phase 3: oxigene.com/pipeline/pipeline/

Bin gespannt wann es hier mal richtig kracht!

Erwartet ihr hier gute Zahlen? Hab mir nun auch mal ne kleine Posi gegönnt :P

geil!

.......endlich gekracht gestern nachbörslich ca.+50 %

OXiGENE Announces Phase 2 Data on ZYBRESTAT to Treat the Eye Disease, Polypoidal Choroidal Vasculopathy (PCV), Presented at the American Academy of Ophthalmology 2012 Annual Meeting


SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced the presentation today of data from a Phase 2 trial of ZYBRESTAT (fosbretabulin) in patients with polypoidal choroidal vasculopathy (PCV), which has features similar to age-related macular degeneration (AMD), a degenerative eye disease.

PCV found more often in individuals of African-American and Asian descent is a disease involving abnormal blood vessels of the macula characterized by recurrent serosanguinous detachment of the retinal pigment epithelium (RPE), submacular hemorrhage and development of subretinal polyps with resulting vision loss. The FAVOR study (Fosbretabulin Against Vasculopathy of the Retina/Choroid) was a randomized, double-masked Phase 2 study conducted in 20 Asian patients at seven clinical trial sites, which compared the outcome of a single intravenous dose of ZYBRESTAT (15, 25, 35 or 45 mg/kg) with placebo. The data showed that there was a transient reduction in polyp activity seen with indocyanine green angiography (ICGA) in a patient treated with 15 mg fosbretabulin and a transient reduction in subretinal fluid seen on optical coherence tomography, or OCT, in a patient treated with 45 mg fosbretabulin. The proportion of eyes with worsened findings on OCT/ICGA was significantly higher in the placebo group (p=0.032). These data suggest that ZYBRESTAT even if administered only as a single dose intravenously may produce a transient reduction in both polyp activity and amount of subretinal fluid in patients with PCV, and that further clinical testing with a more practical topical formulation potentially in combination with photodynamic therapy (PDT), may be warranted. No drug-related serious adverse event was observed in the study.

The data were presented at the 2012 annual meeting of the American Academy of Ophthalmology, being held in Chicago, in a poster titled, "Phase 2 Clinical Trial of Intravenous Fosbretabulin in the Treatment of Polypoidal Choroidal Vasculopathy (Fosbretabulin Against Vasculopathy of the Retina/Choroid: FAVOR Study)" by Timothy Y. Y. Lai, MD, FRCS, FRCOphth , Chinese University Hong Kong, et al.

"We believe that ZYBRESTAT has potential as a treatment for PCV and other ocular diseases involving abnormal blood vessel formation, such as age-related macular degeneration, and could potentially improve upon injectable anti-angiogenic agents which are used to treat these diseases, but which may have limited efficacy," said Jai Balkissoon, MD, FACS, Vice President Clinical Development, OXiGENE.

OXiGENE has previously reported positive results from proof-of-concept Phase 2 studies using an intravenous formulation showing that ZYBRESTAT achieved the primary endpoint of stable disease in patients with myopic macular degeneration (MMD). OXiGENE has conducted preclinical studies with topical formulations of ZYBRESTAT which demonstrated attractive pharmacokinetic and safety properties and efficacy in destroying abnormal vasculature in a rat choroidal melanoma model. Data from the FAVOR study could be used to facilitate dose selection decisions for future clinical trials. OXiGENE is seeking collaborators for its ZYBRESTAT ophthalmology program, which could include future development of a topical-route ZYBRESTAT.

About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer. The Company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

The OXiGENE, Inc. logo is available at www.globenewswire.com/newsroom/prs/?pkgid=4969
Safe Harbor Statement

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any or all of the forward-looking statements in this press release, which include the timing of advancement, outcomes, and regulatory guidance relative to our clinical programs, achievement of our business and financing objectives may turn out to be wrong. Forward-looking statements can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to, the inherent risks of drug development and regulatory review, and the availability of additional financing to continue development of our programs.

Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-K, 10-Q and 8-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise. Please refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2011.

CONTACT: Investor and Media Contact:

        ir@oxigene.com

        650-635-7000

Source: OXiGENE, Inc.


News Provided by Acquire Media